• Home
  • NEW DAY MEDICINE
  • 2 (64) 2024
  • 13 -2 (64) 2024 - Abdullayeva U.K., Nabieva D.A. - ANALYSIS OF IL-23 AND YKL-40 IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THEIR CORRELATION WITH DISEASE ACTIVITY LEVELS

13 -2 (64) 2024 - Abdullayeva U.K., Nabieva D.A. - ANALYSIS OF IL-23 AND YKL-40 IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THEIR CORRELATION WITH DISEASE ACTIVITY LEVELS

ANALYSIS OF IL-23 AND YKL-40 IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THEIR CORRELATION WITH DISEASE ACTIVITY LEVELS

Abdullayeva U.K. Bukhara State Medical Institute named after Abu Ali ibn Sina

Nabieva D.A. Tashkent Medical Academy

Makhamatkhodzhayeva H.B. Tashkent Medical Academy

Resume

The study included 90 patients with ankylosing spondylitis (AS) who received inpatient and outpatient treatment, as well as 20 healthy people who were diagnosed with spondylitis in accordance with the modified New York criteria of 1984 and/or classified criteria developed by ASAS specialists for axial spondylitis in 2009. One of the indicators indicating the level of disease activity is the amount of IL-23 and YKL-40 levels were analyzed according to the AS stage. There is a strong negative correlation between IL-23, YKL-40 levels and disease activity indices, with activity indices decreasing as IL-23 and YKL-40 levels decrease, which means that their levels are higher at an early stage of the disease.

Keywords: Ankylosing spondylitis, activity levels, IL-23, YKL-40, correlation analysis

First page

96

Last page

99

For citation: Abdullayeva U.K., Nabieva D.A., Makhamatkhodzhayeva H.B. ANALYSIS OF IL-23 AND YKL-40 IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND THEIR CORRELATION WITH DISEASE ACTIVITY LEVELS//New Day in Medicine 2(64)2024 96-99https://newdayworldmedicine.com/en/article/3758

List of References

  1. Ozgocmen S, Khan MA. Current concept of spondyloarthritis: special emphasis on early referral and diagnosis. Curr Rheumatol Rep 2022;14:409-14.
  2. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23–IL-17 immune pathway. Trends Immunol 2016;27:17-23.
  3. Rueda B, Orozco G, Raya E, Fernandez-Sueiro JL, Mulero J, Blanco FJ et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. / Ann Rheum Dis 2018;67:1451-4.
  4. Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. // Joint Bone Spine 2017;74:249-53.
  5. Chen W-S, Chang Y-S, Lin K-C, Lai C-C, Wang S-H, Hsiao K-H et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. // J Chin Med Assoc 2022;75:303-8.
  6. Colbert RA, Deodhar AA, Fox D, Gravallese EM, Khan MA, McGonagle D et al. Entheses and bones in spondyloarthritis: 2018 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). // J Rheumatol 2019;36:1527-31.
  7. Wang X, Lin Z, Wei Q, Jiang Y, Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. // Rheumatol Int 2019 29:1343-7.
  8. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. // Clin Rheumatol 2021;30:269-73.
  9. Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. // Rheumatol Int 2015;25:280-4.
  10. Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. // Curr Opin Rheumatol 2018;20:392-7.

    file

    download